Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2014

View Archived Issues

Discovery Laboratories awarded SBIR grant for aerosolized KL4-surfactant

Phase III topline results for Intarcia's ITCA-650 for type 2 diabetes

Biofrontera reports preliminary results from phase III trial of Ameluz

Novel prophylactic human cytomegalovirus vaccine shows promise in vivo

Phase I trial of lirilumab in combination with elotuzumab begins

Eleven Biotherapeutics reports topline data from phase II study of EBI-005

Prophylix Pharma to begin phase I/II trials of NAITgam for prevention of FNAIT

Preclinical activity of a novel long-lasting antimycotic echinocandin

Clinical results presented for the novel cell-based anti-HIV therapy, SB-728-T

IL-10-modified autologous dendritic cells administered to patients with multiple sclerosis

BMS selects NeurOp NMDA receptor modulator for development for depression

Oxford BioTherapeutics and Berlin Chemie/Menarini select second anticancer antibody-drug conjugate

Novel analgesic compounds synthesized at Esteve

IBI-20089 and ranibizumab combination is well tolerated in phase I trial in AMD

Santen confirms closing of asset purchase agreement with Merck & Co.

PEGPH-20 receives orphan drug designation for pancreatic cancer

Novel IRAK-4 inhibitors disclosed by Biogen Idec

FDA grants orphan drug status to chariSMA for spinal muscular atrophy

Treatment begins in phase II study of RPC-4046 for eosinophilic esophagitis

AbbVie divulges novel PDE10A inhibitors

U.S. investigators synthesize novel anti-C. difficile antibodies

Bristol-Myers Squibb reports new KCNA5 channel blockers for arrhythmia

BioMarin Pharmaceutical presents novel HDAC inhibitors

Novartis prepares new IDH inhibitors for cancer

Actimmune receives U.S. orphan drug designation for Friedreich's ataxia

Boehringer Ingelheim presents phase III results for linagliptin/pioglitazone FDC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...